amycretin vs retatrutide Ozempic: Clinical Trial Comparisons Cagrilintide vs retatrutide: amylin analogue

What's New: July 2026 Update TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients Eli Lilly's pivotal Phase 3 obesity trial met all primary and key secondary endpoints 45.3% of patients on 12mg lost 30% of body weight surgical-level outcomes confirmed in the largest retatrutide trial to date 104-week extension: patients with BMI 35 reached up to 30.3% average weight loss weight loss did not plateau at 80 weeks TRANSCEND-T2D-1 CONFIRMED (topline March 2026, published June 2026): First completed Phase 3 trial in type 2 diabetes up to -2.0% HbA1c reduction and 16.8% weight loss in 537 patients, a separate program from TRIUMPH OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a baseline of 58.6 events/hour NDA on track: Industry estimates continue to expect Q4 2026 filing following TRIUMPH-1 and TRIUMPH-4 data TRIUMPH-2 and TRIUMPH-3 results still expected later in 2026 this page updates monthly Current Status: Where Things Stand Retatrutide is an investigational medication developed by Eli Lilly

Results Patients who microdose GLP-1s often notice improvements in appetite control and cravings within the first several weeks

Comprehensive support Our team will work with you to develop a personalized treatment plan, integrating nutrition, exercise, and lifestyle coaching to maximize your results

From our read, it looks like levels were about one and a half times higher, not twice as high.) The authors also reported that the 10-grambut not the 0-gram or 5-gramdose blunted feelings of hunger and increased feelings of fullness for the first 1 hours after eating the meal, though the differences were so small that its hard to believe they were statistically significant